IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no safety signals of concern and have further demonstrated immunologic response that approximates the response seen in convalescent individuals. The purpose of this phase 2b/3 trial is to document the non-inferiority of IIBR-100 vs. an already-approved vaccine for COVID-19.
STUDY RATIONALE:
The SARS-CoV-2 virus is responsible for the COVID-19 pandemic, perhaps the deadliest in 100
years. The pandemic emerged from Wuhan Province in China in December 2019 and was declared by
the WHO Director-General a Public Health Emergency of International Concern on 30 January
2020. Early cases have been reported in Israel around February 2020, and at the time this
protocol is being drafted. The virus has spread to 190 countries with more than 198 million
confirmed cases and more than 4.2 million confirmed deaths as of August 2, 2021 (WHO website
https://covid19.who.int/).
In an effort to curb the pandemic, the Israel Institute for Biological Research (IIBR) has
developed a replication-competent recombinant VSVΔG-spike vaccine (rVSV-SARS-CoV-2-S,
IIBR-100), in which the glycoprotein of VSV is replaced by the spike protein of the
SARS-CoV-2 virus. Pre-clinical data suggested IIBR-100 as a safe, efficacious, and protective
vaccine against SARS-CoV-2 infection. In addition, clinical experience from over 20,000
subjects vaccinated with Ervebo®, an Ebola vaccine developed by Merck & Co. and licensed by
FDA in 2019, also supports the safety of the VSV-ΔG backbone. An overlapping Phase I/II study
in Israel is showing a good safety profile. This study is intended to support late-stage
clinical studies and eventual mass immunization of the Georgian population.
STUDY DESIGN:
This is a Phase IIb/3, prospective, randomized, comparator-controlled, observer-blind,
multi-center non-inferiority study.
Subjects will receive two intramuscular (IM) injections of the IIBR-100 (prime-boost)
separated by 28 days consisted of 1 ml replicating viral rVSV SARS-CoV-2-S vaccine or active
comparator. Injection will be performed at Day 0 and Day 28±2d in the deltoid muscle and will
be followed through 12 months post last vaccination.
Follow-up (FU) visits will occur 1, 2 and 4 weeks, as well as, 2 ,3, 6, 9, and 12 months post
last vaccination.
The primary outcome will be PCR+ infection with COVID-19 six months after vaccination. Key
secondary outcome will be serologic immunity.
Reactogenicity will be assessed at these visits, and blood will be drawn for immunogenicity
assays. Additional safety and reactogenicity data will be solicited via electronic diary and
telephone calls to subjects performed 1 and 2 days post each vaccination.
Reactogenicity will be measured by the occurrence of solicited injection site reaction and
systemic reaction from the time of each vaccination through 7 days post each vaccination.
Unsolicited non-serious Adverse Events (AEs), Serious adverse events (SAEs), new-onset
chronic medical conditions (NOCMCs) and medically-attended adverse events (MAAEs) will be
collected through 12 months after the last vaccination.
Clinical safety laboratory evaluations will be performed at screening, as well as immediately
prior to and 7 days post each vaccination.
Drug: IIBR-100
Administration of IIBR-100 vaccine
Drug: Active Comparator
Administration of a currently-approved vaccine for COVID-19
Inclusion Criteria:
- Males or females, ages 18 to 85 (inclusive) at the time of screening.
- Negative PCR and no presence of ELISA antibody titers to SARS-CoV-2 at screening.
- No clinically significant abnormalities in hematology, blood chemistry, or urinalysis
laboratory tests at screening.
- Must agree not to enroll in another study of an investigational agent prior to
completion of the study.
- Normal oral temperature, pulse rate no greater than 100 beats per minute (sinus
rhythm) and controlled blood pressure (in the case of hypertensives under treatment,
below 140/90 mmHg).
- Subjects must be able to understand the requirements of the study and must be
accessible and willing to comply with the study procedures even under lock down
conditions.
- Ability to provide informed consent -
Exclusion Criteria:
- History of severe local or systemic reactions to any vaccination or a history of
severe allergic reactions or known allergy to the components of the vaccine, including
allergy to rice.
- Receipt of investigational product (except of confirmed placebo in IIBR20-001 study)
up to 30 days prior to screening or ongoing participation in another clinical trial
(except of IIBR20-001 trial).
- Receipt of licensed vaccines within 14 days of planned study immunization and any AE's
possibly related to licensed vaccine immunization at Day 0.
- Inability to observe possible local reactions at the injection sites due to a physical
condition or permanent body art.
- Known hemoglobinopathy or coagulation abnormality (subjects treated by anticoagulation
or anti platelets are not excluded).
- New onset of fever >37.8ºC AND [cough OR shortness of breath OR anosmia/ageusia], or
any other inter current illness within 14 days prior to screening
- Factors that increase risk to the subject to severe disease per CDC guidance including
the following risk factors (in any case of ambiguous grading, decision will be made
per investigator's best clinical judgement): Cancer [ongoing malignancy or recently
diagnosed malignancy in the last five years, not including non-melanotic skin cancer],
Chronic Kidney Disease (eGFR<60 mL/min/1.73 m^2), liver disease (ALT or AST) > 1.5 ×
ULN; or alkaline phosphatase and direct bilirubin > ULN (total bilirubin may be up to
2 × ULN as long as direct bilirubin is equal to or below the ULN); or PT INR > 1.25),
COPD; Immunocompromised state from solid organ transplant; Obesity (BMI≥30kg/m2);
Serious heart conditions, such as heart failure, coronary artery disease, or
cardiomyopathies; Sickle cell disease; Type 1/2 diabetes mellitus (HbA1C>8.0%, per
medical history questioning or records) ); Asthma; Cerebrovascular disease; Cystic
fibrosis, uncontrolled hypertension that does not respond to therapy, Pulmonary
fibrosis, Thalassemia.
Anticipating the need for immunosuppressive treatment within the next 6 months. Clinically
significant (by means of potentially risking the subject or that would be potentially
detrimental to the results of the study) medical condition, physical examination findings,
clinically significant abnormal laboratory results, or past medical history with clinically
significant implications for current health or for severe COVID-19, per the investigator.
Any progressive or severe neurologic condition/disorder, dementia, seizure disorder, or
history of Guillian-Barré syndrome.
- Known or suspected impairment of the immune system including rheumatic, connective
tissue or vascular disease of autoimmune origin
- Clinically significant abnormal CBC results in WBC, hemoglobin, hematocrit, or
platelets.
- Clinically significant abnormal urinalysis: RBC, protein, or glucose only.
- Positive serology for: hepatitis B surface antigen, hepatitis C, HIV.
- Known or suspected illness caused by coronaviruses, SARS-CoV 1, and Middle East
Respiratory Syndrome (MERS)-CoV..
- Received any prior vaccine against a coronavirus.
- Receipt of blood/plasma products or immunoglobulin, from within 60 days before study
intervention administration or planned receipt throughout the study.
- Immunosuppressive medications received within 90 days before screening. (Not including
[1] corticosteroid nasal spray for allergic rhinitis; [2] topical corticosteroids for
mild, uncomplicated dermatitis; or [3] oral/parenteral corticosteroids given for
non-chronic conditions not expected to recur [length of therapy 10 days or less with
completion at least 30 days prior to vaccination].)
- History of alcohol or drug abuse per clinical judgement within 5 years prior to study
vaccination (excluding cannabis)
- Participants who, in the judgment of the investigator, will be unlikely to comply with
the requirements of this protocol.
- Any other significant finding that in the opinion of the investigator would increase
the risk of the individual having an adverse outcome from participating in this study.
Jonathan C Javitt, MD, MPH
484-254-6134
CEO@nrxpharma.com
Ronya Rubinstein, JD
484-254-6134
rrubinstein@nrxpharma.com
Jonathan C Javitt, MD, MPH, Study Chair
NRx Pharmaceuticals, Inc.